Options
Mesothelin與上皮性卵巢癌病人其化學治療反應的關聯性
Correlation between Mesothelin and Chemotherapeutic Response in Patients of Epithelial Ovarian Carcinoma
Date Issued
2007
Date
2007
Author(s)
Huang, Chia-Yen
DOI
zh-TW
Abstract
Objective: Ovarian cancer is one of the leading cause of death among all gynecologic malignancies. The standard treatment of epithelial ovarian cancer (EOC) includes maximally debulking surgery followed by adjuvant chemotherapy. However, resistance to chemotherapy is an important issue while managing patients with EOC. Mesothelin, a secreted glycoprotein, was originally identified on mesothelial cells, mesotheliomas and ovarian cancers. The definite function of mesothelin is still to be clarified. This study is to investigate if the expression levels of mesothelin would correlate with chemotherapeutic response of patients with EOC.
Methods: Ninety eight patients with EOC received operation and postoperative adjuvant chemotherapy were enrolled. Patients with progressive disease or with recurrence within 6 months after completion of chemotherapy were defined as resistant group. Patients without recurrence or with recurrence more than 6 months after completion of chemotherapy were defined as sensitive group. Their clinical and pathologic items were recorded. Expression of mesothelin in ovarian cancer tissue was measured by quantitative competitive RT-PCR (QC RT-PCR) and real-time quantitative PCR (RQ-PCR) methods. The results were correlated to clinical data and outcome of these patients.
Results: The expression of mesothelin in ovarian cancer tissue was significantly higher in patients of resistant group than in sensitive group (p<0.05). In addition, high grade tumors also expressed higher level of mesothelin than those with low grade tumors (p<0.05 ). Patients with mesothelin over-expression had significantly shorter disease free survival than those with normal expression of mesothelin (10.8 months v.s.20.2 months; p<0.05). Patients with over-expression of mesothelin had a poorer overall survival than those with normal expression of mesothelin in serous type of EOC (Log Rank Test: p<0.01).
Conclusions: The expression level of mesothelin in ovarian cancer tissue might be a predictor for the possibility of chemotherapy resistance for patients of EOC.
Methods: Ninety eight patients with EOC received operation and postoperative adjuvant chemotherapy were enrolled. Patients with progressive disease or with recurrence within 6 months after completion of chemotherapy were defined as resistant group. Patients without recurrence or with recurrence more than 6 months after completion of chemotherapy were defined as sensitive group. Their clinical and pathologic items were recorded. Expression of mesothelin in ovarian cancer tissue was measured by quantitative competitive RT-PCR (QC RT-PCR) and real-time quantitative PCR (RQ-PCR) methods. The results were correlated to clinical data and outcome of these patients.
Results: The expression of mesothelin in ovarian cancer tissue was significantly higher in patients of resistant group than in sensitive group (p<0.05). In addition, high grade tumors also expressed higher level of mesothelin than those with low grade tumors (p<0.05 ). Patients with mesothelin over-expression had significantly shorter disease free survival than those with normal expression of mesothelin (10.8 months v.s.20.2 months; p<0.05). Patients with over-expression of mesothelin had a poorer overall survival than those with normal expression of mesothelin in serous type of EOC (Log Rank Test: p<0.01).
Conclusions: The expression level of mesothelin in ovarian cancer tissue might be a predictor for the possibility of chemotherapy resistance for patients of EOC.
Subjects
上皮性卵巢
預後
mesothelin
化學治療
抗藥性
epithelial ovarian cancer
prognosis
chemotherapy
drug-resistance
SDGs
Type
text
File(s)
No Thumbnail Available
Name
ntu-96-P94421007-1.pdf
Size
23.31 KB
Format
Adobe PDF
Checksum
(MD5):3cf8b45d04f9f260a9d2c39c040c06f9